Dr. Jochen H. Lorch, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
676 N Saint Clair St Ste 850
Chicago, IL 60611
Who else practices at this address →
Cook County includes primary care (3% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 32
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 398
Licensed in Illinois since 1999, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
IL license 036100716 (first issued 1999; active) · MA license 224308
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Northwestern Medicine Central Dupage Hospital Winfield, IL
- Northwestern Memorial Hospital Chicago, IL
- Northwestern Lake Forest Hospital Lake Forest, IL
- Palos Community Hospital Palos Heights, IL
Medical groups
- Northwestern Medical Faculty Foundation (4,503 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 398
- Services billed
- 107,739
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, ferric carboxymaltose, 1 mg | 8,250 | 11 |
| Injection, nivolumab, 1 mg | 7,760 | 17 |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 6,120 | 22 |
| Injection, fosaprepitant, 1 mg | 5,400 | 26 |
| Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 5,180 | 47 |
| Injection, pembrolizumab, 1 mg | 4,400 | 15 |
| Injection, denosumab, 1 mg | 2,520 | 16 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 1,419 | 17 |
| Injection, bortezomib, 0.1 mg | 1,089 | 20 |
| Injection, dexamethasone sodium phosphate, 1 mg | 668 | 47 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Levothyroxine Sodium Other prescribers in Chicago, IL | 37 |
| Prochlorperazine Maleate Other prescribers in Chicago, IL | 23 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 3 payments worth $3,900 in total to this clinician.
| Eisai Inc. | $1,963 |
|---|---|
| Janssen Scientific Affairs, LLC | $1,763 |
| Exelixis Inc. | $175 |
| Consulting Fee | $3,725 |
|---|---|
| Food and Beverage | $175 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Eisai Inc. Feb 26, 2025 | Consulting Fee Lenvima · Oncology | $1,963 |
| Janssen Scientific Affairs, LLC Dec 18, 2025 | Consulting Fee | $1,763 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 5 companies. The companies reported $1,193,172 in research payments for these studies, mostly to the institutions running them.
- A randomized, double-blind, placebo-controlled Phase III study to evaluate the efficacy and safety of dabrafenib plus trametinib in previously treated patients with locally advanced or metastatic, radio-active iodine …
Novartis Pharmaceuticals Corporation - An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
Astellas Pharma Global Development - A phase 2 study of XL092 as first line in radio iodine refractory thyroid cancer
Exelixis Inc. - A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head …
Exelixis Inc. - A single arm phase II open-label study to investigate safety and clinical activity of cemiplimab in pts with previously treated recurrent or advanced NUT Midline Carcinoma
Regeneron Pharmaceuticals, Inc. - A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
Takeda Pharmaceuticals U.S.A., Inc. · Completed · NCT04420884
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.